Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab

In conclusion, we demonstrate for the first time that MEPED therapy is highly effective in a patient with Hodgkin's disease who has been refractory to ICPi. Sustained CR was achieved over 11 months after initiation of MEPED therapy. Further studies on a larger patient cohort should be performed.PMID:38444946 | PMC:PMC10912635 | DOI:10.3389/fphar.2024.1334233

Source: Cancer Control - March 6, 2024 Category: Cancer & Oncology Authors: K Reuthner P Aubele K Menhart P Rath D C Harrer W Herr J Hahn M Vogelhuber D Heudobler F Lueke A Reichle M Grube Source Type: research